Retinal Vein Occlusion Treatment Market Size, Share | Report 2022-2030
The global retinal vein occlusion treatment market was estimated at USD 18.31 billion in 2021 and it is expected to surpass around USD 34.88 billion by 2030, poised to grow at a CAGR of 7.42% from 2022 to 2030.
Retinal Vein Occlusion (RVO) is a condition where blockage of central and branch retinal veins that are important for the supply of blood to the center for pumping and purification. Vein blockage causes vision loss. Several factors have been identified as being associated with RVO conditions, including hypertension, cardiovascular diseases, and glaucoma. It can also cause ischemia, retinal traction, macular edema, and neurovascular complications. The diagnosis of the disease can be done by using optical coherence tomography, fluorescein angiography, and laboratory tests for secondary conditions.
The increasing prevalence of atherosclerosis and diabetes is expected to drive market growth. According to the International Diabetes Federation (IDF), around 537 million adult population suffered from diabetes in 2021 and this number is projected to reach 643 million by 2030 and 783 million by 2045. Thus, increasing the prevalence of secondary conditions may increase the prevalence of RVO and support market growth.
Currently, no treatment is available to reverse retinal vein occlusions. However, there are several medical therapies available to limit complications from the RVO. Some of these therapies include anti-VEGF injections, corticosteroid drugs, focal laser therapy, and pan-retinal photocoagulation therapy. The anti-VEGF injection therapy is considered a first-line treatment option for macular edema patients with either BRVO or CRVO.
Significant improvements have been demonstrated in macular edema patients who are on anti-VEGF therapy. Corticosteroids such as dexamethasone implant (OZURDEX) are considered second-line therapy for patients with chronic macular edema. Bevacizumab is also used as an off-label for the treatment of patients with neovascularization and macular edema in BRVO and CRVO.
Furthermore, increasing approval of medicines for the treatment of patients with RVO positively contributes to market growth. For instance, in September 2021, the Food and Drug Administration (FDA) approved the first biosimilar drug Byooviz (ranibizumab-nuna) developed by Samsung Bioepis, for the treatment of patients with macular degeneration disease and other eye conditions including RVO. This approval is expected to boost market growth.
However, the high cost associated with retinal occlusion therapy treatment limits the prescription of drugs and restrains the market growth. Based on the BMC Ophthalmology study 2021, treatment with ranibizumab for BRVO and CRVO patients costs around USD 449.17 and USD 454.75 per quality-adjusted life years (QALY) in China. Thus, the introduction of the new product with high safety & efficacy and low cost is anticipated to drive market growth.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 18.31 billion |
| Revenue Forecast by 2030 | USD 34.88 billion |
| Growth rate from 2022 to 2030 | CAGR of 7.42% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Disease Type, Treatment, End-user, Region |
| Companies Covered |
Novartis AG, Bosch Healthcare Solutions GmbH, Bayer AG, Bayer AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., and Samsung Bioepis |
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Retinal Vein Occlusion Treatment Market
5.1. COVID-19 Landscape: Retinal Vein Occlusion Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Retinal Vein Occlusion Treatment Market, By Disease Type
8.1. Retinal Vein Occlusion Treatment Market, by Disease Type, 2022-2030
8.1.1 Central Retinal Vein Occlusion (CRVO)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Branch Retinal Vein Occlusion (BRVO)
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Retinal Vein Occlusion Treatment Market, By Treatment
9.1. Retinal Vein Occlusion Treatment Market, by Treatment, 2022-2030
9.1.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Corticosteroid Drugs
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Retinal Vein Occlusion Treatment Market, By End-user
10.1. Retinal Vein Occlusion Treatment Market, by End-user, 2022-2030
10.1.1. Hospital & Clinics
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research and Academics
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Retinal Vein Occlusion Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.1.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.2.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.3.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.5.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Treatment (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 12. Company Profiles
12.1. Novartis AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bosch Healthcare Solutions GmbH
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bayer AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Regeneron Pharmaceuticals Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AbbVie Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Teva Pharmaceutical Industries Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Samsung Bioepis
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers